SCHEMBL7935665

SCHEMBL7935665

CCOC(=O)c1nc2ccc(C)cc2nc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 1/20 0.51
ALDH1A1 P00352 4/20 0.48
MAPT P10636 4/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 1/20 0.48
KDM4E B2RXH2 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
OPRK1 P41145 2/20 0.44
TARBP2 Q15633 2/20 0.44
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
NQO2 P16083 1/20 0.41
CYP1A2 P05177 1/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12574451 1.00 GLP1R (0.51) GLP1RALDH1A1MAPTHPGDLMNA
SCHEMBL17601553 0.89 GLP1R (0.51) GLP1RALDH1A1MAPTKDM4ETARBP2
SCHEMBL2021734 0.86 TSHR (0.53) GLP1RALDH1A1MAPTHPGDLMNA
SCHEMBL31345627 0.86 TSHR (0.53) GLP1RALDH1A1MAPTHPGDLMNA
SCHEMBL2021091 0.86 TSHR (0.53) GLP1RALDH1A1MAPTHPGDLMNA
SCHEMBL31345645 0.86 TSHR (0.53) GLP1RALDH1A1MAPTHPGDLMNA
SCHEMBL2411055 0.85 TSHR (0.48) GLP1RALDH1A1MAPTHPGDLMNA
SCHEMBL2405581 0.85 TSHR (0.48) GLP1RALDH1A1MAPTHPGDLMNA
SCHEMBL2019580 0.85 MAPT (0.49) GLP1RALDH1A1MAPTHPGDKDM4E
SCHEMBL6304568 0.85 GLP1R (0.68) GLP1RALDH1A1MAPTL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE10A, PDE12, PDE9A GLP1R 739/4885ALDH1A1 866/4885MAPT 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.